23 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
categories, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied …
Achievement
Lead in TCR Innovation
Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied …
Achievement
Lead in TCR Innovation
Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
secrets and know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how … application.
Biosimilars and Exclusivity
The Biologics Price Competition and Innovation Act, or BPCIA, established a regulatory scheme authorizing the FDA
6-K
EX-99.1
IMCR
Immunocore Holdings plc
20 Jul 22
Securities Purchase Agreement
4:06pm
Wong, M.D.
Name:
Roderick Wong, M.D.
Title:
Director
RTW INNOVATION MASTER FUND, LTD.
By:
/s/ Roderick Wong, M.D.
Name:
Roderick Wong, M.D.
Title
6-K
EX-99.2
IMCR
Immunocore Holdings plc
20 Jul 22
Securities Purchase Agreement
4:06pm
, M.D.
Title:
Director
RTW INNOVATION MASTER FUND, LTD.
By:
/s/
Roderick Wong, M.D
Name:
Roderick Wong, M.D.
Title:
Director
RTW VENTURE FUND LIMITED
6-K
EX-99.1
xm29f ndtu
9 Jun 22
Immunocore Appoints Siddharth Kaul to its Board of Directors
4:12pm
6-K
EX-99.3
h5vlyncgd q3edfeq3r
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.2
31290w
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
zi1q49cmogeihftft
24 Aug 21
Current report (foreign)
4:33pm
6-K
EX-99.3
vix0zwn
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
gzqxhpzw
25 Mar 21
Annual report (foreign)
7:01am
424B4
5i696cbvx6is 8ex3k
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1/A
giv4z8rar88038acgz
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1/A
nkjq4i p5mgighaqw
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1
EX-10.6
fs5gc
15 Jan 21
Registration statement (foreign)
4:57pm
F-1
g82wm8xizte 9o6xs
15 Jan 21
Registration statement (foreign)
4:57pm
F-1
EX-10.15
t336k trrg
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.14
c4y9r5b1
22 Dec 20
Draft registration statement (amended)
12:00am